Mednax Center for Research, Education and Quality   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Sunrise FL United States (1979)

Organization Overview

First Clinical Trial
2010
NCT01402050
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Mednax Center for Research, Education, Quality and Safety

Active Ingredients

Drugs in Phase 4 Trials (1)

voxelotor (Oxbryta) (1 trial)

Drugs in Phase 3 Trials (5)

betamethasone (celestone) (2 trials)

epoetin (Epogen) (1 trial)

fish oil (Omegavan) (1 trial)

progesterone (progestasert) (1 trial)

sodium chloride (2 trials)

Drugs in Phase 2 Trials (2)

buprenorphine (1 trial)

morphine (1 trial)

Drugs in Other Trials (1)

dinoprostone (prostin e2) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Sickle Cell (Phase 4)

Asphyxia (Phase 3)

Asphyxia Neonatorum (Phase 3)

Brain Diseases (Phase 3)

Cholestasis (Phase 3)

Neonatal Abstinence Syndrome (Phase 2)

Obstetric Labor, Premature (Phase 3)

Premature Birth (Phase 3)

Rupture (Phase 3)

Substance Withdrawal Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9